Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Academic Drug Discovery 2016

Academic Drug Discovery 2016

Date: Tuesday, 22 March 2016 - Wednesday, 23 March 2016
Location: Cambridge, UK

Keynote Speakers

Jeffrey Conn

Jeffrey Conn
Director, Vanderbilt University School of Medicine

Sir Tom Blundell

Sir Tom Blundell
Professor, University of Cambridge


SELECTBIO is pleased to announce Academic Drug Discovery 2016, which will be held on 22 - 23 March 2016 in Cambridge, UK. The event is part of our Cambridge Workshop Series. 

Attracting a global audience of researchers, academics, group leaders, directors and the global heads of leading academic and open innovation drug discovery centres, this event will explore the current challenges and opportunities faced in academic drug discovery. 

In recent years pharmaceutical companies have moved away from conducting early-stage preclinical research in-house and are instead partnering with academic institutions to pursue programmes around emerging targets. This has resulted in significant opportunities for academic-based drug discovery and development centres. 

If you work in drug discovery research you will benefit from the expert knowledge and insights provided by academic and industry leaders who are successfully demonstrating models of collaborative drug discovery. 

Agenda Topics

  • Fragment Based Drug Discovery
  • Models For Success
  • New Lead Identification
  • Open Innovation

Sponsorship and Exhibition Opportunities

Exhibition Team,
+44(0)1787 315110

Confirmed Speakers to date

Chas Bountra, Chief Scientist, University of Oxford
Justin Bryans, Director of Drug Discovery, Medical Research Council Technology
James Chen, Executive Director, HTBC, Stanford University
Martin Drysdale, Head of Drug Discovery Programme, The Beatson Institute for Cancer Research
Mikael Elofsson, Professor, University of Umeå
Timothy Hemesath, Director, Biotherapeutics Site Biology and Operations Lead, Centers for Therapeutic Innovation (CTI), Pfizer
Richard Houghten, President, Torrey Pines Institute for Molecular Studies
Annika Jenmalm Jensen, Consortium Director, CBCS Director, LCBKI, Karolinska Institutet
Philip Jones, Head of Drug Discovery, Institute for Applied Cancer Science. MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center
Stuart McElroy, Head of Biology, European Screening Centre Newhouse , University of Dundee
Marc Nazare, Group Leader Medicinal Chemistry, Leibniz-Institut für Molekulare Pharmakologie FMP, Berlin
Christian Ottmann, Associate Professor, Technische Universiteit Eindhoven
Olivia Rossanese, Head of Biology and Reader, CR UK Cancer Therapeutics Unit, Institute of Cancer Research
Frank Schleifenbaum, Head of Product Management and Marketing, Berthold Technologies GmbH & Co. KG
David Smith, Principal Scientist, AstraZeneca R&D
Jan Steyaert, Group Leader/Director, Vrije Universiteit Brussels
Edward Tate, Professor of Chemical Biology, Imperial College London
Jessica Vamathevan, Centre for Therapeutic Target Validation (CTTV) Operations Director, GlaxoSmithKline
Roland Wolkowicz, Associate Professor, San Diego State University
Paul Wyatt, Head of the Drug Discovery Unit, University of Dundee

Corporate Sponsors Media Sponsors Networking

Add to Calendar ▼2016-03-22 00:00:002016-03-23 00:00:00Europe/LondonAcademic Drug Discovery 2016Academic Drug Discovery 2016 in Cambridge, UKCambridge,